An EUA for Baricitinib (Olumiant) for COVID-19

Date: December 28, 2020 Issue #:  1614Summary:  The oral Janus kinase (JAK) inhibitor baricitinib (Olumiant– Lilly) has been granted an FDA Emergency Use Authorization (EUA) for treatment of confirmed or suspected COVID-19 in hospitalized patients ≥2 years old who require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO); the EUA requires that baricitinib be u sed in combination with the IV antiviral drug remdesivir(Veklury). Baricitinib has been available for treatment of rheumatoid arthritis since 2018. Remdesivir was recently approved by the FDA for treatment of COVID-19 in hospitalized patients ≥12 years old who weigh ≥40 kg; it is available under an EUA for treatment of other hospitalized patients.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: baricitinib COVID-19 Oluminat remdesivir Veklury Source Type: research